Editor - Melissa Palmer | NYU Langone Medical Center | 10756
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Melissa Palmer

Melissa Palmer
Melissa Palmer
Clinical Professor
Department of Medicine
NYU Langone Medical Center
NYU Langone Medical Center


Dr. Melissa Palmer, MD has been a Hepatologist since 1988. She was in a solo practice devoted to treating and evaluating patients with liver disease until 2009 at which time she became Director of Hepatology at NYU Langone - Plainview. Dr. Palmer had the largest solo- practice devoted to hepatitis and liver disease in the United States. Dr. Palmer left this position to become an independent Hepatology consultant as of January 1, 2012 until June 31 2012, at which time she took the position of Senior Vice President of Clinical Research and Director of Hepatology at Kadmon Corporation a title she presently holds. She remains a Clinical Professor of Medicine at NYU.

Research Interest

Dr. Palmer has performed trials of various experimental medication for the treatment of hepatitis and other liver diseases since 1983 and has been involved in various ways in the approval of every FDA approved drug for Hepatitis and other liver diseases.




Future Treatment of Hepatitis C: What will be the Fate of Ribavirin?

Melissa Palmer
Editorial: J Gastrointest Dig Syst 2013, 3: e113
DOI: 10.4172/2161-069X.1000e113